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Membrane distillation is a thermally driven membrane process for seawater desalination and puriﬁcation at moderate
temperatures and pressures. A hydrophobic micro-porous membrane is used in this process, which separates hot and cold water,
allowing water vapor to pass through; while restricting the movement of liquid water, due to its hydrophobic nature. This paper
provides an experimental investigation of heat and mass transfer in tubular membrane module for water desalination. Diﬀerent
operating parameters have been examined to determine the mass transport mechanism of water vapor. Based on the experimental




as well as the leading cause of cancer death in men and the
second leading cause in females globally [1]. Nonsmall cell
lungcancer(NSCLC)accountsformorethan85% ofalllung
cancers [2]. The prevailing treatment options for NSCLC
comprise surgery, radiotherapy, and chemotherapy, used
either alone or in combination. Although local treatment
modalities like surgery and radiotherapy can provide the
chance for cure in early stages of NSCLC, about 54% NSCLC
patients present with a metastasis disease at diagnosis,
with an overall 5-year relative survival 3.8%, as estimated
in 17 SEER geographic areas in America during 2001–
2007 [3]. However, the option for these patients with
advanced NSCLC whose lesions are mostly unresectable is
limited to systemic therapy, where chemotherapy plays a
predominant role. The use of chemotherapy in the treatment
of this frustrating malignancy, which had a median survival
measured in weeks or months in early days [4], was once
a controversial issue concerning reproducible toxicity and
questionable activity [4–6]. However, with validations of
increasing publications of meta-analyses and randomized
trials,especiallywiththeadventofnovelcytotoxicdrugswith
less toxicity and more activity, chemotherapy has become
the mainstream of the treatment for advanced NSCLC. As
an updated meta-analysis of data from 2714 patients of
16 randomized controlled trials revealed, compared with
supportive care alone, chemotherapy with supportive care
improves 1-year survival rate from 20% to 29% in all
patientswithadvancedNSCLC[7].Chemotherapyincluding
platinum agents and the third generation drugs produces a
cytotoxic eﬀect by blocking cell division or DNA replication.
Lots of randomized clinical studies in an eﬀort to improve
survival and life quality focused on the eﬃcacy of diﬀering
combinations of chemotherapeutic drugs and revealed that
variant combinations of chemotherapy agents produce sim-
ilar response rate and survival [8, 9]. It is generally accepted
that the eﬃcacy of chemotherapy for advanced NSCLC has
reached a plateau [10], with a response rate of 25–35%,
timetoprogression(TTP,thetimefromrandomizationuntil
objective tumor progression) 4–6 months, a 1-year survival2 Journal of Biomedicine and Biotechnology
rate of 30–40%, and a median survival of 8–10 months [11].
Overall, the prognosis for advanced NSCLC remains poor.
With increasingly researches on molecular pathways of
NSCLC in the last decade, aberrations in signaling pathways
and molecules of tumor cells which promote tumor survival,
proliferation, metastasis, and neovascularization have come
to light. The advent of targeted therapy which acts selectively
on the tumor-speciﬁc molecular pathways, and biomarkers
detection which indicates a likely response to a speciﬁc
therapy and guides the treatment choice [12], has brought
the treatment strategy for NSCLC from empiricism into
a new era of personalized therapy. The management of
tumor is not “trial and error” modality any longer, but more
predictive and eﬃcient, with enhanced sensitivity to therapy
and reduced unnecessary toxic eﬀect and costs of likely inef-
fective treatment [13]. Targeted agents, composing mostly
smallmoleculeinhibitorsandmonoclonalsantibodies,block
signaling pathways by binding to intracellular domain to
inhibit downstream signaling or to extracellular domain
of surface receptor and activating immune mechanisms
[14]. The target-signaling pathways or molecules such as
epidermal growth factor receptor (EGFR) and vascular
endothelial growth factor receptor (VEGFR) have already
yielded signiﬁcant improvements in response rate and
progression-free survival (PFS, the time from randomization
until objective tumor progression or death) used alone or
in combination with chemotherapy compared with standard
chemotherapy alone in large randomized clinical studies
[15–19], and drugs of these categories such as erlotinib and
bevacizumab have obtained FDA approval and have been
recommended by National Comprehensive Cancer Center
Network (NCCN) guidelines for subgroups of advanced and
metastatic NSCLC. Many other targeted drugs acting on
various pathways, for instance, heat shock protein (HSP)-
90 inhibitors, insulin growth factor-1 receptor (IGF-1R)
inhibitor, poly(ADP-ribose) polymerase (PARP) inhibitors,
mammalian target of rapamycin (mTOR) inhibitors, his-
tone deacetylase inhibitors and anaplastic lymphoma kinase
(ALK) inhibitors, have also shown promising prospect in
clinical trials [20]. Recent reviews have been published of
development onthesetargetedtherapiesforNSCLC[21,22].
Despite the ever-increasing novel drugs and diﬀering
combinations of standard drugs for the improvement of
survival of the patients with advanced NSCLC, a signiﬁcant
proportion of patients exhibit or acquire resistance and
eventually experience progression [23]. Even in patients
with a positive predictive biomarker undergoing a targeted
therapy that is likely to be eﬀective, primary resistance
is shown in about 30% overall, and disease recurrence
occurs uniformly in patients with an initial response [24–
27]. Moreover, although EGFR mutations in tumors are
believed to be an important predictor of response to EGFR
inhibitors, studies demonstrate that patients who beneﬁt
from EGFR inhibitors are not limited to those whose tumors
have EGFR mutations [28]. Therefore, valid strategy for
response prediction to help clinical management is still
required.
Furthermore, after disease progression, patients often get
to be unsuitable to receive further treatment due to declining
performance status and increased symptom burden [29–
32]. Therefore, it is of great importance to identify early
whether a patient is likely to respond to the current therapy
and whether a resistance has occurs, for it enables an
early termination of ineﬀective therapy and avoidance of
unnecessary toxic eﬀect or costs for those nonresponders,
as well as more chance to receive a more likely to be
eﬀective therapy. In addition, as more novel drugs come into
clinical trials with inconclusive eﬃcacy, an early and valid
identiﬁcation of therapeutic eﬃcacy helps to shorten the
time for assessment and reduce cost.
While improved survival has been widely accepted as the
“gold standard” for establishing clinical beneﬁt in clinical
trials, as an ultimate and long-term outcome, survival is
not practical for early identiﬁcation of therapy eﬀect. As
a consequence, valid surrogates for shortening the time
for therapeutic eﬃcacy assessment have been applied in
clinical trials, which can reﬂect change of tumor and help to
makepredictionoflong-termoutcomes.Liketumormarkers
such as CA-125 in ovarian cancer has been already used
as standard markers in the objective response assessment
[33], in the context of lung cancer today, imaging that
can provide an insight of tumor condition has long been
applied in measurement of antitumor eﬀect. The imaging-
based endpoints like objective response, PFS, and TTP are
commonly used in stage II and III clinical trials. Given
the importance of early assessment of therapeutic eﬃcacy
in clinical practices and investigational therapies, appro-
priate imaging modalities as an essential part in response
assessment are essential. In this review, we will discuss the
current imaging modalities, especially molecular imaging,
that applied in eﬃcacy evaluation of targeted therapy for
advanced NSCLC.
2. CurrentImagingMethods inEfﬁcacy
Assessment of Treatment for NSCLC
2.1. Computed Tomography (CT). With the rapid develop-
ment of cytotoxic drugs since 1960s, there has been an
intense need for an acknowledged standard in anti-tumor
eﬀect assessment. Since the World Health Organization
(WHO) ﬁrst introduced response criteria of cancer in 1979
[34]i na ne ﬀort to introduce a common language to report
results of investigational antitumor therapies, anatomical
imaginghasbecomethestandardwaytodetermineoncology
response in solid tumors. Because of some limitations of
the WHO criteria, an international working group published
the Response Evaluation Criteria in Solid Tumors (RECIST)
guideline in 2000, and updated it in 2009. These criteria have
determined tumor response as complete response, partial
response, progression disease, and stable disease, according
to the change of target lesions size, and have become the
main standards in clinical trials of anti-tumor therapies for
NSCLC where the primary endpoints are objective response
or progression.
Tumor response is believed to be an indicator of drug
eﬀect in traditional anti-tumor trials and was approved by
the FDA in 1996 to be used in investigational oncologicalJournal of Biomedicine and Biotechnology 3
treatments,astoaccelerateapprovalofnewanti-tumordrugs
[35], for a reason that tumor is not likely to shrinkage spon-
taneously. Lots of trials demonstrated that objective tumor
response is associated with longer survival in chemotherapy
for solid tumors [36–39], yet whether tumor response can
predict therapy eﬃcacy remains an issue open to disputes
[40–42]. At the same time, other endpoints such as disease
controlrate(consistingofCR,PR,andSD),PFS,orTTP[43]
areincreasinglyprovedtobemorevalidmeasuresfortherapy
eﬃcacy assessment in clinical trials [44–46]. These anatomy-
based endpoints, speciﬁed by those criteria, are commonly
used in investigational trials of advanced NSCLC. CT with
its high resolution, moderate costs, and availability has been
historicallythemainstayin measurementoflungcancersizes
and still the standard method in present. In addition, it is
also the recommended method in clinic for surveillance and
instructs clinical management.
However, since targeted therapy came into evaluation,
there are concerns about whether morphology-based criteria
thatwasestablishedincytotoxictherapytrialsisanappropri-
ate metrics in eﬃcacy assessment of targeted-therapy, where
tumor shrinkage is not necessary due to an eﬀect of delaying
the tumor growth. It has been observed in diverse tumors
types like metastatic renal cell cancer and GIST [47, 48],
as well as NSCLC [49–51], that relationship between tumor
regression and survival varied widely. Because stability of
disease cannot be interpreted as ineﬀectiveness of a targeted
therapy, the response deﬁned in change of dimension as
am e a s u r eo fe ﬃcacy in targeted therapy is inappropriate.
In this case, endpoints such as PFS or TTP, which focus
on progression rather than regression, might be more
appropriate and are commonly utilized in clinical studies
of targeted therapy. However, these metrics associated with
progression need regular evaluation in trials and cannot
provide information about treatment eﬃcacy before tumor
enlargement occurs and hence cannot be an early predictor
of treatment eﬃcacy, which is vital to optimizing a patient’s
management in clinic or improving eﬃciency of clinical
trials.
2.2. Dynamic Contrast-Enhanced CT (DCE CT). Regarding
the limitation of size-based methodology, metrics other
than size is also proposed to provide information about
tumor response to targeted therapy. DCE CT is also known
as functional CT, which can provide information about
perfusion. Tumor perfusion versus whole-body perfusion
can be measured on images generated following an intra-
venous injection of a contrast agent. A reduction in tumor
perfusion is demonstrated in NSCLC patients responding to
chemotherapy [52]. Similar result is also yielded in a study
on targeted therapy that has an eﬀect of antiangiogenesis
for NXCLC in monitoring response of NSCLC to [53]. In
this study, tumor perfusion is measured with DCE CT at
week 3 and week 6 after starting treatment, and a reduction
of tumor blood ﬂow is observed at week 6. Meanwhile,
tumor density used in combination with size has become a
new imaging paradigm in assessment of targeted therapy for
GIST[54]andmetastaticrenalcellcarcinoma[55].However,
since there is no such study or criteria in NSCLC, whether
combination of tumor density and size is a feasible metrics
in evaluation of therapy for NSCLC is still unclear.
2.3. Dynamic Contrast-Enhanced Magnetic Resonance Imag-
ing (DCE MRI). Although MRI used limitedly in imaging
of NSCLC, DCE MRI has been used in evaluation of
NSCLC perfusion. With this modality, quantitative parame-
ters reﬂecting tumor microvessel perfusion, permeability can
be obtained [56]. DCE MRI has been veriﬁed as a potential
role in eﬃcacy assessment of both cytotoxic agents and
antiangiogenesis targeted-therapy for NSCLC [57, 58].
2.4.MagneticResonanceSpectroscopy(MRS). Byutilizingthe
special property of nuclear isotopes in a strong magnetic
ﬁeld, MRS gives information of tissue metabolites [59]. As
a molecular imaging modality, MRS has a bright prospect in
personalizedmedicine.Ithasbeenreportedthattheaccuracy
in discrimination between normal lung and each cancer type
with proton MRS (1H MRS) was up to 81.5 to 90.7% [60].
However, there is no utilization of MRS available in response
assessment area in NSCLC up to date.
2.5.PositronEmissionTomography(PET). TheadventofPET
brings about a totally new era of molecular imaging. By
detecting the distribution of the radionuclide-labeled tracer
that is involved with some speciﬁc physiological process
within the body, PET makes metabolic change possible to
be visualized in vivo, which is fundamentally diﬀerent from
conventional anatomy-based imaging modalities. Because
biological features of tumor tissues are usually diﬀerent from
that of normal tissues, this functional imaging technology
that makes qualitative, quantitative, and semiquantitative
analysis available is especially useful in oncology imaging,
playing a role in disease diagnosis, staging and restaging, and
therapeutic response evaluation. In addition, since there are
various biologic compounds participating diﬀerent physio-
logical processes, by developing diverse radionuclide-labeled
tracers, we can acquire tumor information in an optimal way
according to speciﬁc tumor or explore diﬀerent physiologic
features of tumor. While depicting an imaging on molecular
characteristics of diﬀerent tissues, PET can sometimes be
imprecise in anatomical location. For this reason fusion of
PET with traditional modality is developed and comes into
application, combining molecular formations with high-
resolution anatomical structures. The multimodalities of
PET/CT and PET/MRI are currently in practical application
with promising prospect.
The positron-emitting isotopes of oxygen, carbon, nitro-
gen, and ﬂuorine which are the building components of bio-
logical substances are the commonly used labels for tracers
for PET. A large spectrum of radiopharmaceuticals has been
developed associating with various metabolic pathways. 2-
[18F]ﬂuoro-2-deoxy-D-glucose(18F-FDG)reﬂectingglucose
metabolism is most widely used among all the tracers, with
general acceptance in assessment of oncologic therapies. 18F-
FDG is a modiﬁed glucose molecular where the hydrox-
ylgroup (OH) of glucose is replaced with 18F, which has4 Journal of Biomedicine and Biotechnology
a half-life of 110 minutes. Once being taken up into a
cell, it cannot be further metabolized. Therefore, diﬀerent
levels of accumulation of 18F-FDG are reﬂections of diverse
energetic need. It is rational to consider that malignant cells
will decrease glucose requirement due to direct or indirect
damages. Clinical investigations have validated a reduction
in 18F-FDG uptake that occurs in oncological tissues after
anticancer treatment in various tumors including NSCLC
and is closely correlated with ﬁnal outcome of therapy [61].
3-[18F] ﬂuoro-3-deoxy-L-thymidine (18F-FLT), a thymidine
analogue, as a biomarker of proliferation, is another tracer
often investigated in studies on NSCLC.
Radioimmunoimaging has been developed in recent
years with increasing knowledge of molecular pathways of
cancer cells. Based on a fundamental much alike targeted
therapy, by modifying the tracer which target speciﬁc molec-
ular of tumor cells, radioimmunoimaging helps provide
tumor molecular information and thereby has a predictive
value in response to targeted therapy and contributes to
individualized medicine [62–64].
Since metabolic change in tumor always takes place ear-
lier than anatomic change, PET has great advantage in early
evaluationoftreatmenteﬃcacy.Regardingtothewidespread
utilization of PET in assessment of therapy assessment,
European Organization for Research and Treatment of
Cancer (EORTC) and the National Cancer Institute (NCI)
proposedguidelinesin1999and2006,respectively,intending
to standardize the methodology of data acquisition and
analysis of 18F-FDG PET scans [65, 66]. A prospective trial
assessed the relationship between PET-evaluated response
and clinical outcomes by evaluating on-treatment changes
in 18F-FDG and 18F-FLT PET imaging among patients with
NSCLC treated with targeted therapy and veriﬁed that it is
possible to achieve high reproducibility of scan acquisition
methodology,aslongasstrictimagingcomplianceguidelines
are mandated in the study protocol [67]. Furthermore, the
relevance for the prediction of clinical beneﬁt of targeted
therapy using diﬀerent quantitative parameters for PET
with both 18F-FDG and 18F-FLT in patients with advanced
NSCLC, early 18F-FDG PET and 18F-FLT PET can predict
PFS regardless of the method used for standardized uptake
value (SUV) calculation although several indicators like
SUVmax measured with 18F-FDG might be more robust
to use for early response prediction [68]. All these eﬀorts
oﬀer a promising prospect of robust application of this
new modality in eﬃcacy evaluation of tumors. With more
targeted drugs acting on various mechanisms increasingly
coming out, as well as diverse tumor metabolic character-
istics, further researches are still required to oﬀer a valid
methodology for PET as a biomarker for early evaluation of
targeted therapy.
While conventional imaging modalities are fraught with
diﬃculties in early response assessment to cytostatic tar-
geted therapy, 18F-FDG PET meets these challenges both
theoretically and practically. Although the reliability and
powerfulness of 18F-FDG PET in predicting therapeutic
eﬃcacy in NSCLC has been veriﬁed in chemotherapy in the
last few years [69–72], there are fewer clinical studies on its
eﬃciency in early prediction of outcome in targeted therapy
except for gastrointestinal stromal tumor (GIST) [73–75].
However, preclinical studies have shown evidences that PET
may be a promising biomarker for targeted therapies [76–
79].
2.6.Single-PhotonEmission-ComputedTomography(SPECT).
SPECT is also a molecular imaging technique, detecting
tracer labeled with radionuclide emitting single gamma rays.
The dual modality of SPECT/CT has been used in lung
cancer diagnosis [80]. The most investigated trace used in
treatment of lung cancer is 99mTc-methoxyisobutylisonitrile
(99mTc-MIBI), which is reported to play a role in recognition
of chemoresistance of tumor cell [81] and thus has been used
in prediction of response to chemotherapy for NSCLC. A
systematic review of the literature revealed that 99mTc-MIBI
SPECT can accurately identify patients with lung cancer who
will respond to chemotherapy, with an overall sensitivity
of 94%, speciﬁcity of 90%, and accuracy of 92% [82]. In
comparison with PET, SPECT has a lower sensitivity, and the
use of SPECT in assessment of treatment of NSCLC is still
limited.
2.7. Ultrasound. Ultrasound generates images by detecting
changes of sound speed caused by various tissue densities.
Since lung is ﬁlled with air which hardly echoes, ultrasound,
together with a more recent utilization as endoscopic ultra-
sound (EUS), is not a usual technique used in NSCLC except
for mediastinal staging or guiding ﬁne needle aspiration or a
metastasis lesion evaluation.
3. Molecular ImaginginResponse Evaluation
of Targeted Therapy for NSCLC
Molecular imaging modalities are now under evaluation in
targeted therapy for advanced NSCLC although limitedly. In
various agents targeting diverse pathways of cancer cell, there
areonlyseveralagentstargetingEGFR,andVEGFRpathways
have been evaluated by molecular imaging, entirely PET in
clinical or preclinical studies.
3.1.EGFRPathway. EGFR(alsoknownasHER[humanEGF
receptor] and ErbB1) is member of the human epidermal
growth factor receptor family. By triggering the down-
stream signaling pathways involving phosphatidylinositol-3-
OH kinase (PI(3)K)/AKT/mammalian target of rapamycin
(mTOR)and RAS/RAF/MEKand signal transducerand acti-
vator of transcription (STAT) [83], the activation of EGFR
contributes to tumor growth and progression, including
proliferation, maturation, angiogenesis, invasion, metastasis,
and inhibition of apoptosis [84]. Overexpression or aber-
rant activation of EGFR is frequent in NSCLC [85, 86],
and inhibition of EGFR is a rational anticancer strategy,
which have been validated in clinical practice. EGFR is a
transmembrane glycoprotein, consisting of an extracellular
ligand-binding domain, a transmembrane region, and an
intracellular tyrosine kinase domain [87]. Two classes of
agents targeting EGFR are used in clinical practice: tyrosine
kinase inhibitors (TKIs) and monoclonal antibodies.Journal of Biomedicine and Biotechnology 5
3.1.1. EGFR TKIs. TKIs are small molecules that inhibit
phosphorylation of EGFR intracellular tyrosine kinase by
competing with ATP, leading to cell circle delay, inhibition
of angiogenesis and apoptosis [88, 89]. In all the agents of
EGFR TKIs being evaluated in clinical or preclinical studies,
erlotinib is the only EGFR-targeting agent approved by FDA
for the treatment of NSCLC. Geﬁtinib is another EGFR TKI
that has been extensively investigated.
The value of 18F-FDG PET in predicting eﬃcacy of EGFR
antagonist was validated in a preclinical study performed
in 2006 [77]. A dramatic decrease in 18F-FDG uptake was
observed at as early as 2 hours after treatment in geﬁtinib-
sensitive cell lines, while no measurable changes in 18F-FDG
uptake were seen in geﬁtinib-resistant cells.
A clinical study for early prediction of the eﬃcacy of
geﬁtinib for NSCLC conducted in 2007 monitored tumor
response by both CT and 18F-FDG PET [90]. In this study,
two of the ﬁve NSCLC patients who exhibited stable disease
according to RECIST criteria at 4 weeks after initiation of
treatment but with long-term PFS (12.9 and 12.5 months)
showed a marked decrease in 18F-FDG uptake (measured
by SUVmax) within 2 days of treatment initiation, while
SUVmax increase on day 2 had proved progressive disease
based on CT evaluation. Although conclusions can be hardly
drawn due to the small sample size, it did show the potential
of 18F-FDG PET in early response evaluation for targeted
therapy.
Another study observed an increase of SUVmax as mea-
sured with 18F-FDG PET after discontinuation of treatment
with erlotinib or geﬁtinib, due to progressive disease accord-
ing to RECIST, and reintroduction of erlotinib or geﬁtinib
again resulted in decreases in SUVmax [91]. A subsequent
introduction of everolimus, the mTOR inhibitor, led to
further decrease in SUVmax and tumor size after 3 weeks of
combination therapy in 5 of the 10 patients, suggesting that
sometumorcellsremainsensitivetoEGFRblockageafterPD
occurs according to RECIST.
A prospective multicenter trial evaluated response of
seventy-four patients with advanced NSCLC to erlotinib
treatmentwithonlyPET/CTscans[62],furtherveriﬁedearly
18F-FDG PET response is associated with improved PFS and
OS, even in the absence of subsequent RECST evaluation
with CT.
18F-FLT PET was also applied to early detection of tar-
geted therapy eﬃcacy. A striking and reproducible decrease
in 18F-FLTuptakewasexhibitedinerlotinib-sensitivetumors
after two days of treatment and translated into dramatic
tumor shrinkage four days later [92]. Another phase II
clinical trial assessed the use of 18F-FDG PET and 18F-FLT
PET in NSCLC patients following erlotinib therapy [93].
Thisstudyenrolledthirty-fourpreviouslyuntreatedpatients,
demonstrated an that early 18F-FDG response (cutoﬀ value:
30% reduction in the peak standardized uptake value)
predicted signiﬁcantly longer PFS, OS, and nonprogression
after 6 weeks of therapy with erlotinib, while early 18F-FLT
responsewasonlyassociatedwithsigniﬁcantlylongerPFS.In
particular, this study demonstrated early 18F-FDG PET can
identify those patients who could be beneﬁted from erlotinib
even without the knowledge of EGFR mutation.
3.1.2. Monoclonal Antibodies. EGFR-directed monoclonal
antibodies exert an anticancer action by binding to the
extracellular domain of the EGFR. Among all EGFR
antibodies, cetuximab has been investigated extensively
in treatment of NSCLC. A large phase III randomized
trial shows that adding cetuximab to chemotherapy (cis-
platin/vinorelbine) slightly increases overall survival (11.3
versus 10.1 months, P = 0.04) [94]. Other monoclonal
antibodies directing EGFR are still in investigation in clinical
trials.
A phase II trial evaluating 18F-FDG PET and CT as
endpoints for assessing eﬃcacy of cetuximab in combination
with chemotherapy for advanced gastric or gastroesophageal
junction adenocarcinoma showed that 18F-FDG PET could
correctly diﬀerentiate responders from nonresponders, with
a median TTP 16 months and 11 months, respectively
[95]. No clinical studies have been performed regarding
molecular imaging in treatment of NSCLC with EGFR-
targeted monoclonal antibodies, but the use of 18F-FLT
PET has been investigated in a study of human lung
cancer xenografts [96] demonstrated that SUVmax in tumor
tissue signiﬁcantly decreased versus nontreated control
on day 3 after treatment with cetuximab (P<0.01),
while no diﬀerence in CT image was visualized until
day 8.
3.2. VEGFR Pathway. VEGFR pathway plays an important
role in angiogenesis, a process of endothelial cell division
and migration resulting in formation of new capillaries [97].
Angiogenesis is critical to tumor growth and metastasis, and
enhanced VEGF and its receptors expression is found in
av a r i e t yo ft u m o r s[ 98]; thus, blockage of this pathway
is an attractive strategy for anticancer treatment. VEGFR
is a transmembrane receptor tyrosine kinase speciﬁcally
expressed at the surface of endothelial cell [99]. Various
antiangiogenic agents have developed in the last few years,
and VEGFR-directed monoclonal antibodies and VEGFR
TKI are the two classes of VEGFR agents currently used in
studies of NSCLC antiangiogenesis treatment. Use of DCE
MRI imaging as well as PET has been evaluated in this
therapy concerning its eﬀects on tumor vasculature. Despite
the limit use of DCE MRI in evaluation of antiangiogenesis
in NSCLC, DCE MRI is frequently used in other tumors.
As a review exhibited, anti-angiogenic therapies do not
always result in reductions of blood ﬂow in the short
term, and DCE MRI kinetic response relationships are not
universally strong across all tissue sites for all drugs [100].
In treatment for patients with cancer other than NSCLC,
18F-FDG PET exhibited a promising prospect in monitoring
antiangiogenesis eﬀect of VEGFR-directed pathway [100]. In
VEGFR TKI no study with molecular imaging is available at
present.
Bevacizumab is a humanized monoclonal antibody
directed at VEGF. It gained FDA approval based on an
Eastern Cooperative Oncology Group (ECOG) conducted
study [101], in which an increase in survival (12.3 versus
10.3 months) was observed in selected NSCLC patients when
added Bevacizumab to standard chemotherapy.6 Journal of Biomedicine and Biotechnology
Forty-seven chemonaive patients with advanced NSCLC
treated with bevacizumab and erlotinib underwent both 18F-
FDG PET and DCE MRI scan after 3 weeks of treatment
[58], >20% decrease in SUV as measured with 18F-FDG PET
is well predicative for longer PFS (9.7 versus 2.8 months;
P = 0.01), while >40% decrease in Ktrans (the endothelial
transfer constant) as assessed by DCE MRI did not predict
for longer PFS though most tumors have a decrease in Ktrans
value after 3 weeks of treatment.
4. Conclusions andFutureDirections
This paper reviews the currently available studies of molec-
ular imaging used as early prediction of eﬃcacy of targeted
therapyforpatientswithNSCLC.Forpatientswithadvanced
NSCLC, although the application of chemotherapy does
prolong the OS comparing with supportive care alone [7],
the prognosis of NSCLC remains poor, with a median
survival of mere 8–10 months [11]. Nevertheless, it is
validated that diﬀerent combinations of chemotherapeutic
drugs produce similar response rate and survival [7, 8]a n d
theeﬃcacyofchemotherapyforNSCLCisgenerallyaccepted
as having reached a plateau. Targeted therapy, developing
withtheincreasingknowledgeoftumormolecularpathways,
has an approach of blocking speciﬁc pathways of tumor cells
instead of conventional cytotoxic eﬀect. This new therapy
for NSCLC has been investigated in many clinical trials and
yielded signiﬁcant improvement in RR and PFS. As a focus
of current studies on therapy for NSCLC, increasing diverse
targeted agents is now being investigated in clinical trials or
preclinical studies. Meanwhile, the development of targeted
agents highlights the need of a robust modality in eﬃcacy
assessment because the current prevailing anatomy-based
criteriaestablishedonthebasisofnumerouspreviousstudies
on chemotherapy can no longer satisfy the requirement for
early diagnosis.
Along with molecular metabolic mechanisms of tumor
cells that increasingly come to light, rapid development of
molecular imaging has taken place in recent years [102]. By
directly visualizing and measuring the biological process in
vivo [103], molecular imaging enables early assessment of
response to anticancer treatment. Although molecular imag-
ing modalities such as PET, SPECT, and MRS are involved in
diagnosis of NSCLC, PET with diﬀerent radiotracers is the
primary modality that has been investigated in early predica-
tion of targeted therapy for NSCLC. Despite limited studies
are available by now regarding the application of PET in this
area, the outcome is encouraging, exhibiting utilization of
PET in response evaluation, and outcome prediction is feasi-
ble and accurate. Obviously, more investigations are needed.
More researches on molecular imaging in early prediction
of targeted therapy eﬃcacy should be done considering
encouraging outcomes of the available studies and inﬁnite
prospect of diverse molecular imaging modalities.
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